Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Other Non-Current Assets of $21.1 million for Q2 2026, up 322.16% year-over-year from $5.0 million in Q2 2025, and down 10.17% quarter-over-quarter from $23.5 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Other Non-Current Assets for 9 consecutive years, with $21.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 322.16% year-over-year to $21.1 million; the TTM figure through Jun 2026 stood at $21.1 million (up 322.16% YoY), while the FY2024 annual figure was $5.0 million, changed N/A from the prior year.
- Other Non-Current Assets declined to $21.1 million in Q2 2026 per MDGL's latest filing, from $23.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $23.5 million in Q1 2026 and bottomed at $5.0 million in Q2 2024.
- Historically, Other Non-Current Assets has averaged $9.3 million across 3 years, with a median of $5.0 million in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets changed 0.0% — and 2026, when it jumped 369.96%.
- Madrigal Pharmaceuticals' Other Non-Current Assets stood at $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then jumped by 322.16% to $21.1 million in 2026.
- Business Quant data shows MDGL's Other Non-Current Assets at $21.1 million in Q2 2026, $23.5 million in Q1 2026, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 21.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.11 Mn |
| Mar 31, 2026 | 23.50 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Sep 30, 2015 | 226,000.00 |
| Jun 30, 2015 | 278,000.00 |
| Mar 31, 2015 | 564,000.00 |
| Dec 31, 2014 | 305,000.00 |
| Sep 30, 2014 | 331,000.00 |
| Jun 30, 2014 | 358,000.00 |
| Mar 31, 2014 | 384,000.00 |
| Dec 31, 2013 | 1.41 Mn |
| Sep 30, 2013 | 433,000.00 |
| Jun 30, 2013 | 464,000.00 |
| Mar 31, 2013 | 481,000.00 |
| Dec 31, 2012 | 458,000.00 |